心房颤动治疗的持久性：下一个主要障碍。 - Suppr

Suppr

超能文献

Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle.

作者信息

Hylek Elaine M

机构信息

Department of Internal Medicine, Boston University, Boston, Massachusetts, United States.

出版信息

Thromb Haemost. 2018 Dec;118(12):2018-2019. doi: 10.1055/s-0038-1676101. Epub 2018 Nov 19.

DOI:10.1055/s-0038-1676101

PMID:30453349

Abstract

摘要

相似文献

Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle.

Thromb Haemost. 2018 Dec;118(12):2018-2019. doi: 10.1055/s-0038-1676101. Epub 2018 Nov 19.

Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.

J Med Econ. 2015 Jun;18(6):399-409. doi: 10.3111/13696998.2015.1007210. Epub 2015 Feb 9.

Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.

J Comp Eff Res. 2018 Jul;7(7):685-691. doi: 10.2217/cer-2017-0081. Epub 2018 May 29.

Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.

Clin Ther. 2016 Mar;38(3):545-56.e1-6. doi: 10.1016/j.clinthera.2016.01.008. Epub 2016 Feb 5.

Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.

Curr Cardiol Rep. 2015 Aug;17(8):61. doi: 10.1007/s11886-015-0618-4.

Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.

PLoS One. 2018 May 3;13(5):e0196361. doi: 10.1371/journal.pone.0196361. eCollection 2018.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.

J Med Econ. 2017 Sep;20(9):952-961. doi: 10.1080/13696998.2017.1341902. Epub 2017 Jun 22.

Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis.

Am J Surg. 2015 Dec;210(6):1095-102; discussion 1102-3. doi: 10.1016/j.amjsurg.2015.07.005. Epub 2015 Sep 18.

引用本文的文献

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.

Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A42-A55. doi: 10.1093/eurheartj/suab152. eCollection 2022 Feb.

Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.

CMAJ Open. 2020 Dec 18;8(4):E877-E886. doi: 10.9778/cmajo.20200055. Print 2020 Oct-Dec.

Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation.

Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):251-260. doi: 10.1093/ehjcvp/pvaa052.

Atrial Fibrillation in Older People: Concepts and Controversies.

Front Med (Lausanne). 2019 Aug 8;6:175. doi: 10.3389/fmed.2019.00175. eCollection 2019.

Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry.

Med Sci Monit. 2019 Apr 11;25:2649-2657. doi: 10.12659/MSM.915875.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验